Table 2 Patients’ demographics and preoperative clinical characteristics
Characteristic | Non-elderly group (n = 100) | Elderly group (n = 50) | P |
|---|---|---|---|
Age (years), mean ± SD | 65.0 ± 6.9 | 77.2 ± 2.1 | < 0.001 |
Sex (male/female) | 84 / 16 | 42 / 8 | 1.000 |
Performance status (0/1) | 99 / 1 | 50 / 0 | 0.367 |
Comorbidity (%) | |||
Anya | 28 (28%) | 23 (46%) | 0.030 |
Cardiovascular diseasea | 10 (10%) | 12 (24%) | 0.026 |
Respiratory disease | 3 (3%) | 4 (8%) | 0.186 |
Cerebrovascular disease | 7 (7%) | 4 (8%) | 0.823 |
Renal dysfunction | 1 (1%) | 2 (4%) | 0.234 |
Diabetes mellitus | 11 (11%) | 8 (16%) | 0.393 |
History of cancer (%) | 16 (16%) | 7 (14%) | 0.747 |
Brinkman index ≥1000 (%) | 31 (31%) | 17 (34%) | 0.711 |
Excessive alcohol consumption | 57 (57%) | 26 (52%) | 0.562 |
Body mass index, mean ± SD | 21.0 ± 3.1 | 21.1 ± 2.8 | 0.721 |
Blood test, median (range) | |||
Total lymphocyte count (/mm3) | 1600 (500–3400) | 1450 (500–2900) | 0.071 |
Albumin (g/dl) | 4.1 (3.0–5.0) | 3.9 (2.9–4.9) | 0.092 |
Cholinesterase (IU/l) | 276 (117–462) | 248 (96–369) | 0.015 |
Cholesterol (mg/dl) | 188 (101–360) | 184 (118–261) | 0.579 |
Creatinine (mg/dl) | 0.8 (0.2–1.6) | 0.9 (0.5–1.6) | 0.077 |
CEA (ng/ml) | 2.5 (0.4–9.5) | 2.5 (0.9–20.1) | 0.987 |
SCC (ng/ml) | 1.2 (0.3–7.9) | 1.3 (0.5–5.4) | 0.371 |
PNI, median (range) | 49.5 (34.5–60.0) | 46.3 (35.0–57.5) | 0.019 |
CONUT score, median (range) | 1 (0–5) | 1 (0–5) | 0.733 |
Neoadjuvant treatment (%) | 47 (47%) | 21 (42%) | 0.562 |